5 Buy-Rated Stocks with Latest Insider Purchases
Robert James Wills, a director at Oncternal Therapeutics Inc (NASDAQ:ONCT), bought 3,086 shares of Oncternal Therapeutics Inc (NASDAQ:ONCT) at $8.96 per share.
Oncternal Therapeutics Inc. (ONCT)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Two Sigma Advisors John Overdeck And David Siegel | 0 | $0 | -100% | 0% |
| 2. | Renaissance Technologies Jim Simons | 0 | $0 | -100% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.96 | 3,086 | Director | 10,000 | 2024-04-08 | Filing | |
| $8.48 | 6,914 | Director | 6,914 | 2024-03-28 | Filing | |
| $9.04 | 266 | Director | 29,673 | 2024-02-23 | Filing | |
| $9.04 | 714 | Director | 714 | 2024-02-23 | Filing | |
| $0.36 | 3,000 | Officer | 94,726 | 2023-06-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $9.04 | 980 | Director | 0 | 2024-02-23 | Filing | |
| $14.70 | 2,049 | Officer | 45,936 | 2018-07-16 | Filing | |
| $14.70 | 2,049 | Officer | 45,936 | 2018-07-16 | Filing | |
| $19.01 | 7,351 | Officer | 43,630 | 2018-06-20 | Filing | |
| $19.01 | 9,279 | Officer | 19,453 | 2018-06-20 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 0 | $0 | 0% | |
| 2. | 0 | $0 | 0% | |
| 3. | 0 | $0 | 0% |
News See All
10 Underperforming Stocks Insiders are Buying
In this article, we will take a detailed look at the 10 Underperforming Stocks Insiders are Buying. For a quick overview of such stocks, read our article 5 Underperforming Stocks Insiders are Buying...
Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q4 2023 Earnings Call Transcript
Operator: Greetings, and welcome to Oncternal's Fourth Quarter 2023 Financial Results Call. At this time, all participants are in a listen-only mode.
Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q3 2023 Earnings Call Transcript
Operator: Greetings and welcome to Oncternal Therapeutics third-quarter 2023 financial results conference call. [Operator Instructions]. As a reminder, this conference is being recorded.
Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q2 2023 Earnings Call Transcript
Operator: Greetings and welcome to the Oncternal Second Quarter 2023 Financial Results Call. At this time, all participants are in a listen-only mode.
Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q1 2023 Earnings Call Transcript
Operator: Greetings, and welcome to the Oncternal Therapeutics First Quarter 2023 Financial Results Call. As a reminder, this conference will be recorded.
Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q4 2022 Earnings Call Transcript
Operator: Greetings and welcome to the Oncternal Therapeutics, Inc. Fourth Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Is Oncternal Therapeutics (ONCT) A Good Stock To Buy Now?
At Insider Monkey, we pore over the filings of nearly 817 top investment firms every quarter, a process we have now completed for the latest reporting period.
Billionaire Hedge Funds
